Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• The stock has a consensus rating of "Moderate Buy" from five covering firms (four buys, one sell) with an average 1‑year target of $25.67, while recent analyst moves include Guggenheim cutting its target to $40 (still a buy), Benchmark lowering to $15 (speculative buy) and Weiss reaffirming a sell.
• Shares trade around $6.65 with a 52‑week range of $3.71–$11.00 and a market cap of ~$167.8M, and the company reported a quarter EPS of ($0.82), missing the ($0.46) estimate; consensus expects about ($0.23) for the year.
• Institutions own about 40.42% of the stock, with recent position changes including large increases or new stakes from JPMorgan, State Street, Citadel, Quadrature and Lazard.

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $25.6667.

Several equities research analysts have recently weighed in on UNCY shares. Guggenheim lowered their target price on shares of Unicycive Therapeutics from $46.00 to $40.00 and set a "buy" rating on the stock in a report on Thursday, April 2nd. Benchmark lowered their target price on shares of Unicycive Therapeutics from $21.00 to $15.00 and set a "speculative buy" rating on the stock in a report on Monday. Westpark Capital started coverage on shares of Unicycive Therapeutics in a report on Thursday, February 19th. They issued a "buy" rating on the stock. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Unicycive Therapeutics in a report on Friday, March 27th.

Institutional Investors Weigh In On Unicycive Therapeutics

Large investors have recently made changes to their positions in the company. Lazard Asset Management LLC bought a new stake in shares of Unicycive Therapeutics in the 2nd quarter worth about $55,000. JPMorgan Chase & Co. grew its holdings in Unicycive Therapeutics by 11,698.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company's stock worth $104,000 after acquiring an additional 21,525 shares during the last quarter. Citadel Advisors LLC bought a new stake in Unicycive Therapeutics during the 3rd quarter worth about $182,000. Quadrature Capital Ltd bought a new stake in Unicycive Therapeutics during the 4th quarter worth about $226,000. Finally, State Street Corp grew its holdings in Unicycive Therapeutics by 19.0% during the 4th quarter. State Street Corp now owns 65,227 shares of the company's stock worth $376,000 after acquiring an additional 10,400 shares during the last quarter. Institutional investors own 40.42% of the company's stock.

Unicycive Therapeutics Stock Performance

Shares of UNCY stock opened at $6.65 on Friday. The firm has a fifty day moving average of $6.64 and a 200-day moving average of $5.88. Unicycive Therapeutics has a 52-week low of $3.71 and a 52-week high of $11.00. The stock has a market cap of $167.83 million, a price-to-earnings ratio of -3.06 and a beta of 1.81.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last posted its earnings results on Monday, March 30th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.36). On average, sell-side analysts predict that Unicycive Therapeutics will post -0.23 earnings per share for the current year.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.